ESC
European Society
of Cardiology

Role of smooth muscle cells in coronary artery bypass grafting failure

Kerry Wadey[1], Joshua Lopes[2], Michelle Bendeck[2], and Sarah George[1]*

[1]Bristol Medical School, Research Floor Level 7, Bristol Royal Infirmary, Bristol BS2 8HW, UK; and [2]Translational Biology and Engineering Program, University of Toronto, Toronto, ON M5G 1M1, Canada

Abstract   Atherosclerosis is the underlying pathology of many cardiovascular diseases. The formation and rupture of atherosclerotic plaques in the coronary arteries results in angina and myocardial infarction. Venous coronary artery bypass grafts are designed to reduce the consequences of atherosclerosis in the coronary arteries by diverting blood flow around the atherosclerotic plaques. However, vein grafts suffer a high failure rate due to intimal thickening that occurs as a result of vascular cell injury and activation and can act as 'a soil' for subsequent atherosclerotic plaque formation. A clinically-proven method for the reduction of vein graft intimal thickening and subsequent major adverse clinical events is currently not available. Consequently, a greater understanding of the underlying mechanisms of intimal thickening may be beneficial for the design of future therapies for vein graft failure. Vein grafting induces inflammation and endothelial cell damage and dysfunction, that promotes vascular smooth muscle cell (VSMC) migration, and proliferation. Injury to the wall of the vein as a result of grafting leads to the production of chemoattractants, remodelling of the extracellular matrix and cell–cell contacts; which all contribute to the induction of VSMC migration and proliferation. This review focuses on the role of altered behaviour of VSMCs in the vein graft and some of the factors which critically lead to intimal thickening that pre-disposes the vein graft to further atherosclerosis and re-occurrence of symptoms in the patient.

Keywords   Vascular smooth muscle • Vein graft • Cadherin • Extracellular matrix

This article is part of the Spotlight Issue on Novel concepts for the role of smooth muscle cells in vascular disease.

1. Saphenous vein grafting

Atherosclerosis is the underlying pathology in many cardiovascular diseases. Coronary artery bypass graft (CABG) surgery is the most frequently performed surgical intervention for relieving consequences associated with ruptured or occlusive coronary artery atherosclerotic plaques.[1,2] Surgery entails usage of non-native, un-diseased vessel (most often the saphenous vein, internal mammary artery or radial artery) for diversion of blood from the aorta to the coronary artery, distal to the stenosed region, thereby re-vascularizing cardiac tissue. Despite improvements in surgical techniques and medical management, long-term efficacy of bypass grafts, especially saphenous vein grafts, remains restricted due to complete or significant occlusion (restenosis) of the conduits or continued progression of atherosclerosis in native coronary arteries.[3] Though arterial grafts exhibit superior patency rates to saphenous vein grafts,[4–10] the latter is most commonly used as it is easier to harvest and manipulate, and its length allows for reaching of any coronary artery and making of multiple grafts.[11] However, the prognosis is such that 10–15% of saphenous vein grafts are pre-disposed to early failure within the first year of surgery, and up to 50% suffer late vein graft

failure within 10 years.[1,2,6] Numerous studies have attempted to identify treatments for effectively ameliorating late vein graft stenosis though no validated interventional strategies currently exist. Advances in our understanding of the epidemiology and aetiology of saphenous vein graft failure are thus essential for the design of preventative therapies.

2. Pathogenesis of saphenous vein graft failure

Thrombosis, intimal hyperplasia, and accelerated atherosclerosis are the primary pathophysiological events underlying saphenous vein graft failure (*Figure 1*).[12] Thrombosis typically occurs within 1 month of surgery in 3–15% of patients[13,14] and is a direct consequence of endothelial dysfunction.[12] Disruption to the endothelium is in turn a product of high pressure distension used to overcome vasospasm during surgery and to disrupt the venous valves,[15] and tissue handling during harvesting and implantation of the vein conduit.[16] Focal endothelial loss is most prominent at the sites of anastomosis.[3] After implantation the vein graft is subjected to considerably altered blood flow and wall stress than from its

Figure 1 Early and late vein graft failure. Normal vein structure showing the three layers within the vessel wall: intima, media, and adventitia. Processes involved in early and late vein graft failure. Early vein graft failure is driven by thrombosis. Late vein graft failure is driven by intimal thickening and superimposed atherosclerosis.

original source of the venous system. This is also thought to contribute to endothelial cell damage and loss from the luminal surface.[17] Loss of the endothelial monolayer and endothelial dysfunction induce adherence and accumulation of fibrin, platelets and neutrophils to the luminal surface of the vessel wall[18,19] and causes an attenuation in production of thrombolytic agents, including tissue plasminogen activator (tPA),[20] and thrombomodulin—a protein cofactor normally expressed on the surface of endothelial cells that complexes with thrombin to activate protein C, a potent anti-coagulant.[21] Furthermore, the inherent anti-thrombotic properties of veins are comparatively weak with respect to arteries; for example, expression of anti-coagulant heparin sulphate, and production of platelet activation inhibitors including nitric oxide (NO) and prostacyclin, is notably reduced in veins with respect to arteries.[12,17] The propensity for thrombus formation is also amplified by such factors as intact venous valves, vein distension, reduced flow, and anastomotic error.[3] Thus, even when saphenous vein graft surgeries are performed optimally, there remains an inherent pre-disposition for generation of thrombi. Further endothelial damage and dysfunction is caused after Implantation into the arterial circulation, this is discussed in more detail later in this review.

Intimal hyperplasia is a consequence of VSMC accumulation and their deposition of extracellular matrix (ECM) (*Figure 1*). Most veins display fibrosis of the intimal or medial compartments prior to grafting,[22] though further post-operative intimal thickening can impinge on the lumen by up to 25% within the first 4–6 weeks following surgery.[12] Though rarely

enough to induce significant stenosis alone,[23] intimal hyperplasia serves as a foundation for accelerated, superimposed atherosclerosis.[24] Intimal fibrosis, in part, precipitates from transient ischaemia within the graft. Hypoxia has been detected in the vein graft and it has been proposed that chronic exposure in contrast to transient hypoxia promotes intimal thickening in grafts. In response to hypoxia there is a marked induction of superoxide radical formation in the vessel wall and an attenuation in endothelial cell production of anti-mitotic agents including prostacyclin, NO, and adenosine directly promoting intimal VSMC migration and replication.[25,26] In addition, re-endothelialization over non-occlusive thrombi—platelet and fibrin deposits at the luminal surface—allows for progressive organization of the thrombi into fibrotic tissue; subsequently, platelets release various growth factors and cytokines compounding VSMC proliferation and thereby intimal thickening.[19] Such mitogens are also secreted by endothelial cells, macrophages, and VSMCs themselves.[17,18,27] Neointima formation is further exacerbated by increased wall stress and distension of the vein graft when subjected to pulsatile pressures of the arterial system.[3,12] This is described in more detail later in this review. Elevated tangential stress promotes production of mitogenic agents including platelet-derived growth factor (PDGF), basic fibroblast growth factor (bFGF) and endothelin 1, and inhibits synthesis of anti-proliferative factors such as transforming growth factor-β (TGF-β) and NO.[17,27,28] All these elements combined confer on saphenous vein grafts a high susceptibility to generation of restenotic lesions.

Figure 2 Comparison of venous and arterial cells. Differences in the properties of venous and arterial cells that alter cell behaviour and may contribute to the poor patency of coronary artery vein grafts.

Vein	Component	Artery
Low	VSMC differentiation (contractile)	High
Low	VSMC α-actin, decorin, adhesion to collagen and fibronectin	High
Spindle	VSMC shape	Less-spindle
Small	VSMC size	Larger
High	VSMC proliferation and migration	Low
High	VSMC dedifferentiation (synthetic)	Low
High	VSMC SMemb, PDGFR-β expression	Low
High	VSMC MMP-2 and MMP-9 expression	Low
VEGF-A	Hypoxia induced VSMC migration and proliferation	PDGF-BB
High	EC: acute shear stress induced inflammation	Low

The focus of this review is the role of altered behaviour of VSMCs within the vein graft. This is due to both inherent differences in the composition of the vein and divergent behaviour of venous VSMCs (v-VSMCs) and arterial VSMCs (A-VSMCs), see *Figures 2* and *3*. Within the native vein and artery in their natural environment the VSMCs predominantly exist in a quiescent phenotype. The main function of the VSMC is contraction and thereby regulation of blood flow and pressure. VSMCs are not terminally differentiated and can switch from the quiescent contractile differentiated phenotype to a de-differentiated synthetic phenotype.[29] In veins there is a higher incidence of de-differentiated VSMCs than arteries. This switch occurs in response to a number of stimuli including hypoxia, endothelial dysfunction and inflammation[29] and is also induced prior to grafting by surgical preparation of the vein.[30] De-differentiation involves VSMCs loss if contractile proteins such as α-smooth muscle actin (SMA-α), myosin heavy chain and smoothelin, and enhanced extracellular matrix and inflammatory cytokines production.[31] This phenotypic transformation observed in grafts at 1 month plays a major pathophysiologic role in intimal thickening.

Though the widely accepted rationale for development of neointimal hyperplasia is that mature, quiescent medial VSMCs de-differentiate into proliferative, and synthetic VSMCs,[32–34] over the past decade, an array of studies have identified alternative vascular progenitors that may contribute to the overall neointimal VSMC population. Controversy still remains over the origin of the intimal vein graft cells in vein graft. It is considered by some that intimal cells are exclusively from the vein graft.[35] Others proposed that bone marrow or 'graft-extrinsic' cells are the major source of intimal cells.[36] A more recent study by Liang *et al.* showed that ∼54% of SMA-α-positive cells in the neointima of mouse vein grafts originated from the flanking recipient artery.[37] Interestingly bone marrow cells did not contribute to the SMCs of the neointima in vein grafts. This is consistent with a previous study in which all graft cells migrated from the flanking artery without any contribution from putative progenitor cells in the blood in arterial allografts in mice.[38] Not all the host-derived cells expressed the SMC marker SMA-α (∼10% were negative), which may represent the de-differentiated VSMCs. It is also of note that some of the neointimal VSMCs within the vein graft were from other sources, possibly SMC progenitors,[39,40] endothelial cells,[39,41] or adventitial cells.[32,42] Using nanofibrous vascular grafts interposition into the carotid artery of athymic rats Tang *et al.* demonstrated that multipotent vascular stem cells (MVSC) differentiated into mature VSMCs.[43]

Vein	Component	Artery
Low	Heparan sulphate, Glycosaminoglycans, hyaluronic acid, chrondroitin sulphate	High
Low	Esterified and free cholesterol, phospholipids	High
Low	DNA	High
Low	Protein	High
Low	NO	High
Low	Salusin-β, apelin-36	High
High	Dermatan sulphate	Low
High	Collagen	Low
High	Salusin-α	Low

Figure 3 Comparison of veins and arteries. Structural and compositional differences of veins and arteries that may contribute to the poor patency of coronary artery vein grafts.

However, Liang *et al.* concluded that de-differentiation of SMCs in the anastomosed arteries are the major contributor to intimal thickening.[37] Additional strategies are required to further examine the contribution of MVSCs to intimal thickening, such as a tamoxifen-inducible SMC-Cre reporter and/or SOX10-Cre reporter mice. Whether alternative vascular progenitors play a salient role in the generation of proliferative and synthetic VSMCs in human grafts remains unclear and subject to debate and is most likely dependent on the degree of injury to the graft either during or following the procedure as this influences the release of factors that induce homing of stem cells to the site of injury. To date fate tracing experiments have not been performed in a suitable large animal model of vein grafting to determine directly whether neointimal cells are derived from mature VSMCs or from progenitor cells. Notwithstanding the involvement of progenitor cells, it is still presumed that mature, quiescent medial VSMCs, at least to an extent, participate in intimal thickening, and formation of occlusive lesions.

Beyond the first year following CABG surgery, atherosclerosis is the dominant pathophysiological process responsible for restenosis and saphenous vein graft degeneration (*Figure 1*).[12,44,45] Atheroma development in vein grafts is similar to that in native arteries, though there are a few temporal, histological and topographical discrepancies.[12] Firstly, the progression of atherosclerosis is more rapid in saphenous vein grafts compared to native coronary arteries as chronic endothelial dysfunction[19,46] and pronounced intimal fibrosis[24] observed in the former generate a highly atherogenic environment. Secondly, diseased vein grafts accommodate more inflammatory cells, including foam cell macrophages and multinucleate giant cells,[47] and display higher rates of lipid-uptake and lipid synthesis, than native coronary arteries.[48] Lastly, morphologically, coronary artery vein graft atheromas are diffuse, concentric (*Figure 1*) and show poorly developed or absent fibrous caps and little evidence of calcification, whereas native coronary atheromas are focal, eccentric, and exhibit well-developed fibrous caps and calcification.[47,49–51] However, as with native atheromas, restenotic, and atherosclerotic lesions within grafts are prone to rupture, resulting in the re-occurrence of ischaemic myocardial injury[52]; thus, study of the molecular dynamics underlying this pathology is essential for the design of new and improved treatments.

3. Factors involved in activation of V-vsmcs

In this review, we have focussed on the role of the VSMC in the formation of intimal thickening which pre-disposes the graft to atherosclerosis. There are a number of inherent differences in the composition and cells of the vein and the host artery which may affect the behaviour of the graft cells and thereby contribute to intimal thickening (summarized in *Figures 2* and *3*).

3.1 Composition of vein graft

It has been clearly demonstrated that the composition of saphenous vein and internal mammary artery differs considerably and this may also contribute to the divergent graft patency rates.[53] For example, in comparison to internal mammary artery, saphenous vein has high levels of dermatan sulphate, collagen, and salusin-α, while low levels of heparin sulphate, esterified and free cholesterol, phospholipids, DNA, protein, total glycosaminoglycans, hyaluronic acid, chondroitin sulphate, nitric oxide (NO), salusin-β, and apelin-36. Approximately 65% of the saphenous vein is collagen whilst lower amounts are present in the internal mammary artery.[54] Furthermore, the internal mammary has higher medial elastic lamina than the saphenous vein, providing greater elasticity, and reducing deformation and compliance. Intimal thickening is caused by VSMCs migrating through the internal elastica lamina and invading the intima. Therefore, the internal elastic lamina as a barrier to smooth muscle cells.[55] In addition, this difference in ECM composition and cellularity results in a compliance mis-match between the stiffer vein graft and the artery, this is further exaggerated at the anastomosis.[56] The saphenous vein contains less heparan sulphate than the internal mammary artery due to reduced cellularity.[54] Contrastingly, there is augmented dermatan sulphate in glycosaminoglycans in the saphenous vein than the internal mammary artery, which provides enhanced affinity for LDL and VLDL than other glycosaminoglycans components. This may explain in part why the saphenous vein graft has an enhanced propensity to atherosclerosis.

Divergent secretion of soluble factors may also favour intimal thickening in the vein graft. Saphenous vein secretes less NO,[57] a vasodilator which inhibits thrombosis and is critical for lumen patency,[58] and therefore this is thought to contribute to enhanced intimal thickening and reduced graft patency. Reduced sensitivity of the saphenous vein to vasoactive materials may also contribute to a low patency rate.[54] Moreover, A-ECs secret higher levels of endothelium-dependent relaxation factor (EDRF) than veins which also protects against intravascular thrombus formation. Veins also secrete different types and amounts of vasodilatory substances.[53] Lower amounts of the peptides apelin and salusin in the saphenous vein than arteries and could influence the vasodilatory properties of the graft and thereby patency.

3.2 Differences in vascular cells

In addition, to differences in composition inherent differences in the grafted vascular cells with the host vascular cells may contribute to intimal thickening. A number of studies have demonstrated contrasting properties of A-VSMCs and V-VSMCs. The distinct properties of V-VSMCs may contribute to the intimal thickening and late failure of venous grafts. As hypoxia occurs at the anastomosis of synthetic grafts[59] and arteriovenous fistulas,[60] it is of relevant to determine the effect of hypoxia on VSMC behaviour. VSMC migration and proliferation was enhanced in venous VSMCs compared to arterial VSMCs.[61,62] Interestingly the mechanism of induction also differed, with V-VSMCs utilizing vascular endothelial growth factor (VEGF)-A via VEGF-receptor-1 whilst arterial hypoxia-induced migration and proliferation was predominantly mediated by PDGF-BB.[61,62] It is therefore likely that differential regulation of VSMC migration and proliferation under hypoxia contributes to the differences in intimal thickening observed in vein and arterial grafts despite hypoxia occurring in both types of graft. It should be noted however that a limitation of these studies is the use of umbilical cord cells and future studies utilizing saphenous vein to compare with arterial graft VSMCs and native coronary artery VSMCs would

be beneficial. It has also been proposed that the augmented proliferative responses V-VSMCs to hypoxia compared to A-VSMCs are due to the differential responses of SMC proliferation to hypoxic EC-derived growth factors such as PDGF-AB.[63] Moreover V-VSMCs express higher levels of PDGF-Rβ expression and exhibit transactivation of epidermal growth factor (EGF)-receptor by PDGF-BB. Contrastingly, A-VSMCs, but not V-VSMCs, induce proliferation in response to PDGF-AA, presumably via activation of the PDGF-Rα/JNK1/p27^{kip1} pathway.[64]

V-VSMCs exhibit a more de-differentiated phenotype to A-VSMCs, exhibiting heightened proliferative, and synthetic capacity.[65] In culture it is apparent that V-VSMCs are smaller, more spindle-shaped, and demonstrate higher proliferative and migratory rates than A-VSMCs. Moreover, increased SMemb expression and decreased α-actin is indicative of a more dedifferentiated phenotype in V-VSMCs, as well as enhanced expression of MMP-2, and MMP-9. Additionally, adhesion to both collagen and fibronectin was significantly lower for V-VSMCs than A-VSMCs. Notably, the expression of decorin was significantly higher in A-VSMCs than V-VSMCs and this may contribute to their altered behaviour.[65] Consequently, strategies to enhance decorin expression may be beneficial for retarding vein graft intimal thickening. A limitation of this study is the use of cultured cells and isolation of carotid arteries and jugular veins from rabbits. Future studies are required using human VSMCs from saphenous vein and coronary artery to demonstrate the generality of these findings.

Observed differences in the behaviour of VSMC derived from saphenous vein to A-VSMCs could facilitate development of new pharmacotherapy, directed specifically at venous intimal hyperplasia. Such therapeutic strategies could be formulated to the type of vessel graft and could prevent restenosis in saphenous vein grafts.[64]

Differences in arterial and venous cells may not be restricted to VSMCs, and differences in arterial endothelial cells (A-ECs), and venous endothelial cells (V-ECs) may have important ramifications on vein graft failure. Short-term exposure of V-ECs to high shear stress such as that encountered in the venous graft after implantation into arterial circulation the leads to proinflammatory activation of the ECs by the induction of MAP kinase phosphatase-1.[66] Interestingly, this does not occur in A-ECs. Dexamethasone pre-treatment of the V-ECs, 'arterializes' them by inducing MAP kinase phosphatase-1 and it is therefore possible that this approach may protect veins from inflammation. The observed differences in response of V-ECs and A-ECs may reflect epigenetic memory of the markedly different haemodynamic environments of their origin. The shear stresses in arteries are markedly higher (10–20 dynes/cm^2) than veins (<5 dynes/cm^2). Cultured A-ECs may be pre-adapted to the arterial environment and retain this resistance in culture, whereas v-ECs are primed by the venous environment. There are also non-haemodynamic factors which contribute to the arterial-venous heterogeneity, including epigenetic modifications and cellular signalling pathways that control A-EC and V-EC differentiation in embryonic vessels before circulation of blood.[67] The altered response to shear stress by the V-ECs may lead to the release of inflammatory and pro-proliferative factors that cause activation of the underlying V-VSMCs.

3.3 Injury to graft

The endothelium and VSMCs of the vein graft are damaged during the preparation and the implantation of the vein graft. The graft is injured in various ways: physical damage by the use of instruments used to harvest the vein from the patient's leg, application of high intra-luminal pressure to check for leakage and disruption of the valves, deployment of clips or sutures to seal side branches. Additionally, damage is caused by

implantation into the arterial circulation leading to exposure to high arterial blood pressure and flow causing further damage to the endothelium.[17] The damaged endothelium disrupts the physiological balance of the vein and this is further disturbed by release of factors from damaged VSMCs.[68] The imbalance leads to accelerated VSMC proliferation and is proportional to the degree of injury.[69] This response is considered as a wound healing response that leads to intimal and media thickening in an attempt to become arterialized. However, the thickening of the vein graft ultimately becomes problematic as the required adaptation to the arterial circulation leads to an environment that is susceptible to superimposed atherosclerosis which leads to re-occurrence of symptoms. It would be highly beneficial if grafts could be monitored for the occurrence of arterialization to determine the point at which detrimental superimposed atherosclerosis was initiated and suitable treatments could be applied at this timepoint. However, currently this has not been established in a suitable large animal model or in humans.

3.4 Biomechanical factors

Biomechanical factors are a major contributor to the incidence and distribution of bypass graft disease.[56] Disturbed local haemodynamics are known to be involved in the formation of intimal thickening. It has been illustrated that end-to-side graft –artery implantation is responsible for disturbed flow patterns which make the vein susceptible to remodelling in the occurrence of intimal thickening.[70] Low-wall shear stress and high-wall mechanical stress or strain are two major factors.[71] Additionally, a range of secondary factors are involved including vessel geometry; vessel movement; vessel wall characteristics; and the presence of reflection waves.[72] However, to date no surgical differences have been made to significantly reduce intimal thickening by alteration of biomechanical factors. Increasing the awareness of the effects of the biomechanical factors on the vein graft may facilitate new approaches to reduce the failure rate of coronary artery vein grafts.

It is apparent that flow pattern regulates cell proliferation and migration. Using a venous polymer implant in rats, vortex blood flow induced VSMC migration, and neointimal hyperplasia, whereas the reduced vortex blood flow in the modified vein graft strongly suppressed these effects via the phosphorylation of ERK1/2 and myosin light chain kinase.[73]

Elevated cyclic stretch is thought to be one of the major contributors to intimal thickening due to the differences in the venous and arterial environment.[12] Moreover, mechanical stretch *in vitro* causes a differential effect on VSMCs from different sources. Enhanced proliferation is not observed in A-VSMCs after stretching at 0.05 and 1 Hz when compared with unstretched controls. In contrast, stretching of V-VSMCs both at 0.05 and 1 Hz result significantly augmented proliferation compared with static controls,[74,75] via IGF-1 receptor activation and serum-, glucocorticoid-regulated kinase 1.[76,77] Thereby, it can be proposed that the accelerated V-VSMC proliferation, within vein grafts *in vivo*, is partially the response of the induction of proliferation of V-VSMCs to mechanical stimulation. It is plausible therefor that a biomechanical engineering approach with adaptive training of V-VSMCs prior to grafting could possibly improve vein graft patency.

Speculatively, movement may have an effect on graft patency. At the junction between the stationary aorta and the partially mobile vein graft there may be increased local wall stresses and strains as well as the graft being exposed to a repeated torsional or pendular movement depending on the site of the anastomosis. Experimental external stents which reduce some of the biomechanical forces reduced intimal thickening,[78] however, this did not translate into clinical benefit in humans due to

kinking of the graft within the external stent.[79] Development of a flexible, biodegradable external stent that can surround both the anastamosis and the mid-portion of the graft are essential.

The vein graft is proposed to be subjected to high blood pressure and flow stagnation in systole and high flow-induced high shear stress and potentially erosion in diastole. To examine this Piola *et al.* established an *ex vivo* flow model. They observed that although pulsatile stimulation did not affect vessel wall integrity and size, it caused partial endothelial denudation, apoptosis in the vessel wall, and altered medial and intimal thickness.[80] These data could mimic the early vessel remodelling events in vein grafts.

As mentioned previously the composition of the ECM and the cellularity (and thereby the amount of cell–cell cadherin mediated contacts) of veins differs from that of arteries and may contribute to the altered behaviour of VSMCs in grafts by enhancing migration and proliferation. Therefore, the role of some of the components of the ECM and cadherin contacts in the regulation of VSMC behaviour will be discussed in more detail in the following sections.

3.5 Extracellular matrix

ECM synthesis not only serves as marker of the active VSMC phenotype, but many of the matrix molecules produced are bioactive and regulate proliferation and migration.

3.5.1 Elastin

Elastin is a stable matrix molecule deposited in vessels during embryonic and early neonatal life. It is a hydrophobic protein composed of cross-linked tropoelastin molecules. Intact elastin inhibits VSMC proliferation to help maintain vessel quiescence. Elastin-deficient mice die early after birth from complete arterial occlusion, which is secondary to robust proliferation and migration of VSMCs from the medial into the intimal layer.[81] With the development of vascular disease, there is significant degradation and disruption of elastin. Elastin degradation is mediated by at least three groups of elastases; serine proteases (i.e. neutrophil elastase and cathepsin G), cysteine proteases (i.e. cathepsin L, S, K, and V), and MMPs (i.e. MMP-2, -7, -9, and -12).[82] Elastin degradation results in the accumulation of elastin-derived peptides which have been shown to increase VSMC proliferation and migration.[83]

3.5.2 Type I collagen

Type I collagen is a triple helical molecule composed of heterotrimers of α1 and α2 chains. In intimal hyperplasia type I collagen is found in abundance, and in the context of the injured vessel wall it is present in varied states of assembly or degradation each of which can have distinct effects upon VSMC migration and proliferation. Like elastin, intact or polymeric type I collagen maintains VSMC quiescence, while monomeric or degraded collagen promotes VSMC proliferation and migration. Early studies revealed that plating VSMCs on polymerized collagen resulted in suppression of growth mediated by cyclin dependent kinase inhibitors,[84,85] while treating cells with monomeric or soluble collagen stimulated proliferation.[84,86] Plating on monomeric collagen also decreased the expression of VSMC differentiation markers, and led to the upregulation of the inflammatory adhesion molecule VCAM.[87] *In vivo* studies of the response to injury in pig coronary arteries provided support for this notion, because accumulation of collagen was correlated with the upregulation of cyclin inhibitors and a decrease in VSMC proliferation.[88] Type I collagen also acts via receptor cross-talk between integrins and growth factors to potentiate the proliferative signalling induced by platelet

derived growth factor (PDGF-BB).[89] VSMCs are able to migrate faster across a monomeric collagen matrix than a polymerized matrix.[84,90,91] In fact, proteolysis of the collagen matrix is required for migration in both 2 D and 3 D gels, not just to degrade matrix barriers, but collagen fragments help to break up focal adhesions allowing cell release and translocation.[92,93] There is also evidence that cell deposit new collagen on top of existing matrix to form a provisional matrix more permissive for migration.[94,95] Treatment of cells to inhibit collagen synthesis prevents focal adhesion formation, actin stress fibre assembly, and migration irrespective of the initial matrix used to coat the plate.[96] The differences in response to different physical states of collagen are partially related to the ease with which cells can release from the ECM, however, there is also clear evidence that different physical forms of collagen can trigger activation of distinct signalling pathways.

3.5.3 Type VIII collagen

It is well established that type VIII collagen expression is dramatically increased in vascular injury and disease.[97–100] Type VIII collagen is a short chain, network-forming collagen composed of two chains, procollagen α1(VIII), and procollagen α2(VIII), which are encoded by two separate genes, *Col8a1* and *Col8a2*.[101] Type VIII collagen is central to the control of VSMC proliferation and migration making important contributions to the development of intimal hyperplasia. *In vitro* studies show that type VIII collagen acts as a chemotactic and haptotactic factor for VSMCs.[102,103] VSMCs adhere less strongly to type VIII collagen compared to type I collagen, and addition of type VIII collagen to a polymeric type I collagen matrix allows release and migration of cells across the matrix, suggesting that type VIII collagen can form a provisional matrix.[102] VSMCs isolated from collagen VIII deficient mice (*Col8-/-*) displayed reduced migration, proliferation, and MMP-2 production compared to cells from wild-type mice.[104] The *Col8-/-* cells had prominent actin stress fibres, stable microtubules, and numerous basal focal adhesions, all due to enhanced activation of RhoA.[105] Addition of exogenous type VIII collagen suppressed RhoA, restored MMP-2 activity, and enhanced proliferation and migration in these cells.[105] These studies show that type VIII collagen regulates cytoskeletal configuration and MMP-2 expression to facilitate VSMC migration. *In vivo* studies confirmed the role of type VIII collagen in promoting VSMC proliferation and migration to the neointima. *Col8-/-* mice subject to wire injury of the femoral artery had less VSMC accumulation and less wall thickening compared to *Col8+/+* mice,[106] revealing an important role for type VIII collagen in regulating VSMC migration and infiltration into the vessel neointima. Type VIII collagen[107] expression is mediated by the transcription factor KLF4, which is also a critical factor mediating the VSMC phenotypic switch[107] and therefore type VIII collagen expression would be increased during VSMC de-differentiation, promoting VSMC migration and proliferation.

3.6 Cell–cell contacts–cadherins

The cadherins are a superfamily of transmembrane glycoproteins that mediate homophilic cell–cell adhesions.[108] Cadherin expression is cell-type specific, and the predominant classical cadherin expressed by VSMCs is N-cadherin.[109] Extracellular domain 1 (EC1) of the classical cadherins contains a HAV binding motif, which interacts with cadherins on adjacent cells in a zipper-like fashi. Fibroblast growth factor receptor (FGF-R) also contains an HAV motif, which permits the formation of a heterodimer with EC4 within the N-cadherin molecule.[110] Whilst the extracellular domain of classical cadherins regulates homophilic cell–cell adhesion the intracellular domain modulates cell signalling.

The most-well characterized signalling pathway is the β-catenin/Wnt pathway.[111] Cytoplasmic accumulation of β-catenin facilitates movement of β-catenin to the nucleus where it binds to T-cell factor (TCF), and resulting in up- or down-regulation of downstream genes,[112] including those involved in the cell cycle (cyclin D1[113] and c-myc[114]), and migration [versican,[115] fibronectin,[116] matrix metalloproteinase-7 (MMP-7),[117] and membrane-tethered MMP-1 (MT1-MMP)[118]]. Cell signalling and thereby behaviour is also modulated by cadherins via interaction with Rho GTPases[119] and receptor tyrosine kinases, including FGF-R.[120]

It has been clearly demonstrated that N-cadherin regulates VSMC proliferation and, migration, and that this is mediated at least in part by interaction with the FGF-R (*Figure 2*).[109,110,121–127] VSMC proliferation is inhibited by N-cadherin, via β-catenin signalling.[109] N-cadherin cell–cell contacts are modulated by proteolytic shedding by MMPs including MMP-9 and -12, but not MMP-2 and -14,[125] which frees β-catenin permitting it's movement to the nucleus.[109,127] Inhibiting β-catenin signalling reduces proliferation, due to a reduction in the expression of β-catenin responsive genes, cyclin D1 and p21, which are involved in cell cycle regulation.[126] In cells lacking MMPs 9 and 12 there was less β-catenin signalling, and attenuated cyclin D1 expression, presumably because N-cadherin is maintained and can therefore retain β-catenin at the membrane rather than releasing it for signalling.[125] Discrepant findings for the role of N-cadherin in VSMC migration have been reported. In some studies, it was concluded that N-cadherin was pro-migratory.[128,129] However, in another studies N-cadherin inhibited migration of VSMCs.[130,131]

Loss of cadherins during proliferation leads to the release of free β-catenin which in turn can induce Wnt signalling. Indeed it has been demonstrated that Wnt/β-catenin signalling regulates both VSMC migration and proliferation in various studies.[126,132–142] The compelling evidence for the involvement of Wnt signalling in VSMC proliferation and thereby intimal thickening has led to the suggestion that activation of the Wnt/β-catenin pathway is a marker of culprit VSMCs that lead to intimal. Consequently, targeting Wnt activated VSMCs could reduce intimal thickening. This is supported by the following studies. Firstly, conditional smooth muscle specific deletion of β-catenin reduced intimal thickening in mice.[143] Additionally, the Wnt/β-catenin inhibitor XAV939 inhibited intimal thickening in mice subjected to carotid artery ligation.[144] Two recent studies using the mouse carotid artery ligation model demonstrated that selective suicide of cells with active Wnt signalling retards intimal thickening.[145,146]

4. Summary

In summary, VSMC play a major role in the remodelling of the saphenous vein graft after implantation by contributing to the thickening of the intima. Accelerated intimal thickening in the vein graft is the result of a number of inherent divergent properties of the vein and its vascular cells and the biomechanical and environment factors after implantation as outlined in this review. These result in activation of V-VSMCs and modulation of their behaviour by several factors including ECM and cadherin contacts. The thickened intima is highly susceptible to superimposed atherosclerosis which leads to re-occurrence of symptoms and the need for future treatments. To improve vein graft patency strategies are required to reduce the deleterious biomechanical and environmental factors by altering surgical procedures or by application of treatments which retard the detrimental remodelling of the artery. Identification of the timepoint when beneficial remodelling and arterialization of the vein

transfers to superimposed atherosclerosis would be highly advantageous but required improved imaging techniques or identification of suitable biomarkers.

Conflict of interest: none declared.

Funding

References

1. Eagle KA, Guyton RA, Davidoff R, Edwards FH, Ewy GA, Gardner TJ, Hart JC, Herrmann HC, Hillis LD, Hutter AM Jr, Lytle BW, Marlow RA, Nugent WC, Orszulak TA. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). *Circulation* 2004;**110**: e340–e437.
2. Yusuf S, Zucker D, Peduzzi P, Fisher LD, Takaro T, Kennedy JW, Davis K, Killip T, Passamani E, Norris R. Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. *Lancet* 1994;**344**:563–570.
3. Harskamp RE, Lopes RD, Baisden CE, de Winter RJ, Alexander JH. Saphenous vein graft failure after coronary artery bypass surgery: pathophysiology, management, and future directions. *Ann Surg* 2013;**257**:824–833.
4. Collins P, Webb CM, Chong CF, Moat NE. Radial artery versus saphenous vein patency randomized trial: five-year angiographic follow-up. *Circulation* 2008;**117**: 2859–2864.
5. Desai ND, Cohen EA, Naylor CD, Fremes SE. A randomized comparison of radial-artery and saphenous-vein coronary bypass grafts. *N Engl J Med* 2004;**351**: 2302–2309.
6. FitzGibbon GM, Leach AJ, Keon WJ, Burton JR, Kafka HP. Coronary bypass graft fate. Angiographic study of 1, 179 vein grafts early, one year, and five years after operation. *J Thorac Cardiovasc Surg* 1986;**91**:773–778.
7. Goldman S, Zadina K, Moritz T, Ovitt T, Sethi G, Copeland JG, Thottapurathu L, Krasnicka B, Ellis N, Anderson RJ, Henderson W. Long-term patency of saphenous vein and left internal mammary artery grafts after coronary artery bypass surgery: results from a Department of Veterans Affairs Cooperative Study. *J Am Coll Cardiol* 2004;**44**:2149–2156.
8. Hadinata IE, Hayward PA, Hare DL, Matalanis GS, Seevanayagam S, Rosalion A, Buxton BF. Choice of conduit for the right coronary system: 8-year analysis of Radial Artery Patency and Clinical Outcomes trial. *Ann Thorac Surg* 2009;**88**: 1404–1409.
9. Lytle BW, Loop FD, Cosgrove DM, Ratliff NB, Easley K, Taylor PC. Long-term (5 to 12 years) serial studies of internal mammary artery and saphenous vein coronary bypass grafts. *J Thorac Cardiovasc Surg* 1985;**89**:248–258.
10. Zacharias A, Habib RH, Schwann TA, Riordan CJ, Durham SJ, Shah A. Improved survival with radial artery versus vein conduits in coronary bypass surgery with left internal thoracic artery to left anterior descending artery grafting. *Circulation* 2004; **109**:1489–1496.
11. Sabik JF. Understanding saphenous vein graft patency. *Circulation* 2011;**124**:273–275.
12. Motwani JG, Topol EJ. Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. *Circulation* 1998;**97**:916–931.
13. Bourassa MG. Fate of venous grafts: the past, the present and the future. *J Am Coll Cardiol* 1991;**17**:1081–1083.
14. Fitzgibbon GM, Kafka HP, Leach AJ, Keon WJ, Hooper GD, Burton JR. Coronary bypass graft fate and patient outcome: angiographic follow-up of 5, 065 grafts related to survival and reoperation in 1, 388 patients during 25 years. *J Am Coll Cardiol* 1996;**28**:616–626.
15. Roubos N, Rosenfeldt FL, Richards SM, Conyers RA, Davis BB. Improved preservation of saphenous vein grafts by the use of glyceryl trinitrate-verapamil solution during harvesting. *Circulation* 1995;**92**:31–36.
16. Thatte HS, Khuri SF. The coronary artery bypass conduit: i. Intraoperative endothelial injury and its implication on graft patency. *Ann Thorac Surg* 2001;**72**: S2245–S2252. discussion S2267-2270.
17. Cox JL, Chiasson DA, Gotlieb AI. Stranger in a strange land: the pathogenesis of saphenous vein graft stenosis with emphasis on structural and functional differences between veins and arteries. *Prog Cardiovasc Dis* 1991;**34**:45–68.
18. Dilley RJ, McGeachie JK, Tennant M. Vein to artery grafts: a morphological and histochemical study of the histogenesis of intimal hyperplasia. *Aust N Z J Surg* 1992;**62**: 297–303.
19. Verrier ED, Boyle EM Jr. Endothelial cell injury in cardiovascular surgery. *Ann Thorac Surg* 1996;**62**:915–922.
20. Nachman RL, Silverstein R. Hypercoagulable states. *Ann Intern Med* 1993;**119**: 819–827.
21. Cook JM, Cook CD, Marlar R, Solis MM, Fink L, Eidt JF. Thrombomodulin activity on human saphenous vein grafts prepared for coronary artery bypass. *J Vasc Surg* 1991;**14**:147–151.
22. Thiene G, Miazzi P, Valsecchi M, Valente M, Bortolotti U, Casarotto D, Gallucci V. Histological survey of the saphenous vein before its use as autologous aortocoronary bypass graft. *Thorax* 1980;**35**:519–522.
23. Chesebro JH, Fuster V. Platelet-inhibitor drugs before and after coronary artery bypass surgery and coronary angioplasty: the basis of their use, data from animal studies, clinical trial data, and current recommendations. *Cardiology* 1986;**73**: 292–305.
24. Stary HC, Blankenhorn DH, Chandler AB, Glagov S, Insull W Jr, Richardson M, Rosenfeld ME, Schaffer SA, Schwartz CJ, Wagner WD. A definition of the intima of human arteries and of its atherosclerosis-prone regions. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. *Circulation* 1992;**85**:391–405.
25. Holt CM, Francis SE, Newby AC, Rogers S, Gadsdon PA, Taylor T, Angelini GD. Comparison of response to injury in organ culture of human saphenous vein and internal mammary artery. *Ann Thorac Surg* 1993;**55**:1522–1528.
26. Rao GN, Berk BC. Active oxygen species stimulate vascular smooth muscle cell growth and proto-oncogene expression. *Circ Res* 1992;**70**:593–599.
27. Nguyen HC, Grossi EA, LeBoutillier M III, Steinberg BM, Rifkin DB, Baumann FG, Colvin SB, Galloway AC. Mammary artery versus saphenous vein grafts: assessment of basic fibroblast growth factor receptors. *Ann Thorac Surg* 1994;**58**:308–310, discussion 310–301.
28. Allaire E, Clowes AW. Endothelial cell injury in cardiovascular surgery: the intimal hyperplastic response. *Ann Thorac Surg* 1997;**63**:582–591.
29. Shi N, Chen SY. Mechanisms simultaneously regulate smooth muscle proliferation and differentiation. *J Biomed Res* 2014;**28**:40–46.
30. Johnson JL, van Eys JJM, Angelini GD, George SJ. Injury induces de-differentiation of smooth muscle cells and increased matrix-degrading metalloproteinase activity in human saphenous vein. *Arterioscler Thromb Vasc Biol* 2001;**21**:1146–1151.
31. Campbell GR, Campbell JH. Smooth muscle phenotypic changes in arterial wall hemostasis: implications for the pathogenesis of atherosclerosis. *Exp Mol Pathol* 1985;**42**:139–162.
32. Hu Y, Zhang Z, Torsney E, Afzal AR, Davison F, Metzler B, Xu Q. Abundant progenitor cells in the adventitia contribute to atherosclerosis of vein grafts in ApoE-deficient mice. *J Clin Invest* 2004;**113**:1258–1265.
33. Nguyen AT, Gomez D, Bell RD, Campbell JH, Clowes AW, Gabbiani G, Giachelli CM, Parmacek MS, Raines EW, Rusch NJ, Speer MY, Sturek M, Thyberg J, Towler DA, Weiser-Evans MC, Yan C, Miano JM, Owens GK. Smooth muscle cell plasticity: fact or fiction? *Circ Res* 2013;**112**:17–22.
34. Owens GK, Kumar MS, Wamhoff BR. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. *Physiol Rev* 2004;**84**: 767–801.
35. Cooley BV. Murine model of neointimal formation and stenosis in vein grafts. *Arterioscler Thromb Vasc Biol* 2004;**24**:1180–1185.
36. Zhang L, Freedman NJ, Brian L, Peppel K. Graft-extrinsic cells predominate in vein graft arterialization. *Arterioscler Vasc Thromb* 2004;**24**:470–476.
37. Liang M, Liang A, Wang Y, Jiang J, Cheng J. Smooth muscle cells from the anastomosed artery are the major precursors for neointima formation in both artery and vein grafts. *Basic Res Cardiol* 2014;**109**:431.
38. Hagensen MK, Shim J, Falk E, Bentzon JF. Flanking recipient vasculature, not circulating progenitor cells, contributes to endothelium and smooth muscle in murine allograft vasculopathy. *Arterioscler Thromb Vasc Biol* 2011;**31**:808–813.
39. Diez M, Musri MM, Ferrer E, Barbera JA, Vi P. Endothelial progenitor cells undergo an endothelial-to-mesenchymal transition-like process mediated by TGFbetaRI. *Cardiovasc Res* 2010;**88**:502–511.
40. Zernecke A, Schober A, Bot I, von Hundelshausen P, Liehn EA, Mopps B, Mericskay M, Gierschik P, Biessen EA, C. W. SDF-1α/CXCR4 axis is instrumental in neointimal hyperplasia and recruitment of smooth muscle progenitor cells. *Circ Res* 2005;**96**: 784–791.
41. Chen P-Y, Qin L, Barnes C, Charisse K, Yi T, Zhang X, Ali R, Medina PP, Yu J, Slack FJ, Anderson DG, Kotelianski V, Wang F, Tellides G, Simons M. FGF regulates TGF-beta signaling and endothelial-to-mesenchymal transition via control of let-7 miRNA expression. *Cell Rep* 2012;**2**:1684–1696.
42. Shi Y, O'Brien JE, Fard A, Mannion JD, Wang D, Zalewski A. Adventitial myofibroblasts contribute to neointimal formation in injured porcine coronary arteries. *Circulation* 1996;**94**:1655–1664.
43. Tang Z, Wang A, Yuan F, Yan Z, Liu B, Chu JS, Helms JA, Li S. Differentiation of multipotent vascular stem cells contributes to vascular diseases. *Nat Commun* 2012; **3**:875.
44. Chen L, Theroux P, Lesperance J, Shabani F, Thibault B, De Guise P. Angiographic features of vein grafts versus ungrafted coronary arteries in patients with unstable angina and previous bypass surgery. *J Am Coll Cardiol* 1996;**28**:1493–1499.
45. Douglas JS Jr. Percutaneous approaches to recurrent myocardial ischemia in patients with prior surgical revascularization. *Semin Thorac Cardiovasc Surg* 1994;**6**: 98–108.

46. Boyle EM Jr, Lille ST, Allaire E, Clowes AW, Verrier ED. Endothelial cell injury in cardiovascular surgery: atherosclerosis. *Ann Thorac Surg* 1997;**63**:885–894.

47. Ratliff NB, Myles JL. Rapidly progressive atherosclerosis in aortocoronary saphenous vein grafts. Possible immune-mediated disease. *Arch Pathol Lab Med* 1989;**113**: 772–776.

48. Shafi S, Palinski W, Born GV. Comparison of uptake and degradation of low density lipoproteins by arteries and veins of rabbits. *Atherosclerosis* 1987;**66**:131–138.

49. Kalan JM, Roberts WC. Morphologic findings in saphenous veins used as coronary arterial bypass conduits for longer than 1 year: necropsy analysis of 53 patients, 123 saphenous veins, and 1865 five-millimeter segments of veins. *Am Heart J* 1990;**119**: 1164–1184.

50. Lie JT, Lawrie GM, Morris GC Jr. Aortocoronary bypass saphenous vein graft atherosclerosis. Anatomic study of 99 vein grafts from normal and hyperlipoproteinemic patients up to 75 months post-operatively. *Am J Cardiol* 1977;**40**:906–914.

51. Neitzel GF, Barboriak JJ, Pintar K, Qureshi I. Atherosclerosis in aortocoronary bypass grafts. Morphologic study and risk factor analysis 6 to 12 years after surgery. *Arteriosclerosis* 1986;**6**:594–600.

52. Walts AE, Fishbein MC, Matloff JM. Thrombosed, ruptured atheromatous plaques in saphenous vein coronary artery bypass grafts: ten years' experience. *Am Heart J* 1987;**114**:718–723.

53. Aydin S, Aydin S, Eren MN, Sahin İ, Yilmaz M, Kalayci M, Gungor O. The cardiovascular system and the biochemistry of grafts used in heart surgery. *SpringerPlus* 2013; **2**:612.

54. Sisto T, Yla-Herttuala S, Luoma J, Riekkinen H, Nikkari T. Biochemical composition of human internal mammary artery and saphenous vein. *J Vasc Surg* 1990;**11**: 418–422.

55. Tennant M, McGeachie JK. Blood vessel structure and function: a brief update on recent advances. *Aust N Z J Surg* 1990;**60**:747–753.

56. Ghista DN, Kabinejadian F. Coronary artery bypass grafting hemodynamics and anastomosis design: a biomedical engineering review. *Biomed Eng Online* 2013;**12**: 129.

57. Oku T, Yamane S, Suma H, Satoh H, Koike R, Sawada Y, Takeuchi A. Comparison of prostacyclin production of human gastroepiploic artery and saphenous vein. *Ann Thorac Surg* 1990;**49**:767–770.

58. Kocailik A, Basaran M, Ugurlucan M, Ozbek C, Kafali E, Yerebakan C, Selimoglu O, Banach M, Ucak A, Ogus TN, Us M. Papaverine solution improves preservation of saphenous vein grafts used during cardiac surgery. *Acta Cardiol* 2008;**63**:445–449.

59. Lee E S, Bauer G E, Caldwell M P, Santilli S M. Association of artery wall hypoxia and cellular proliferation at a vascular anastomosis. *J Surg Res* 2000;**91**:32–37.

60. Wan J, Lata C, Santilli A, Green D, Roy S, Santilli S. Supplemental oxygen reverses hypoxia-induced smooth muscle cell proliferation by modulating HIF-alpha and VEGF levels in a rabbit arteriovenous fistula model. *Ann Vasc Surg* 2014;**28**:725–736.

61. Chanakira A, Kir D, Barke RA, Santilli SM, Ramakrishnan S, Roy S, Buch SJ. Hypoxia differentially regulates arterial and venous smooth muscle cell migration. *PLoS ONE* 2015;**10**:e0138587.

62. Chanakira A, Dutta R, Charboneau R, Barke R, Santilli SM, Roy S. Hypoxia differentially regulates arterial and venous smooth muscle cell proliferation via PDGFR-β and VEGFR-2 expression. *Am J Physiol Heart Circ Physiol* 2012;**302**:H1173–H1184.

63. Li L, Blumenthal DK, Masaki T, Terry CM, Cheung AK. Differential effects of imatinib on PDGF-induced proliferation and PDGF receptor signaling in human arterial and venous smooth muscle cells. *J Cell Biochem* 2006;**99**:1553–1563.

64. Li L, Blumenthal D, Terry C, He Y, Carlson M, Cheung A. PDGF-induced proliferation in human arterial and venous smooth muscle cells: molecular basis for differential effects of PDGF isoforms. *J Cell Biochem* 2011;**112**:289–298.

65. Wong AP, Nili N, Strauss BH. In vitro differences between venous and arterial-derived smooth muscle cells: potential modulatory role of decorin. *Cardiovasc Res* 2005;**65**:702–710.

66. Zakkar M, Luong LA, Chaudhury H, Ruud O, Punjabi PP, Anderson JR, Mullholand JW, Clements AT, Krams R, Foin N, Athanasiou T, Leen ELS, Mason JC, Haskard DO, Evans PC. Dexamethasone arterializes venous endothelial cells by inducing mitogen-activated protein kinase phosphatase-1 a novel antiinflammatory treatment for vein grafts? *Circulation* 2011;**123**:524–U141.

67. Aitsebaomo J, Portbury AL, Schisler JC, Patterson C. Brothers and sisters. *Circ Res* 2008;**103**:929–939.

68. Ip JH, Fuster V, Badimon L, Badimon J, Taubman MB, Chesebro JH. Syndromes of accelerated atherosclerosis: role of vascular injury and smooth muscle cell proliferation. *J Am Coll Cardiol* 1990;**15**:1667–1687.

69. Clowes AW, Reidy MA, Clowes MM. Kinetics of cellular proliferation after arterial injury. I. Smooth muscle growth in the absence of endothelium. *Lab Invest* 1983;**49**: 327–333.

70. Bassiouny HS, White S, Glagov S, Choi E, Giddens DP, Zarins CK. Anastomotic intimal hyperplasia: mechanical injury or flow induced. *J Vasc Surg* 1992;**15**:708–716, discussion 716–707.

71. Morinaga K, Okadome K, Kuroki M, Miyazaki T, Muto Y, Inokuchi K. Effect of wall shear stress on intimal thickening of arterially transplanted autogenous veins in dogs. *J Vasc Surg* 1985;**2**:430–433.

72. John LCH. Biomechanics of coronary artery and bypass graft disease: potential new approaches. *Ann Thoracic Surgery* 2009;**87**:331–338.

73. Goldman J, Zhong L, Liu SQ. Negative regulation of vascular smooth muscle cell migration by blood shear stress. *Am J Physiol Heart Circ Physiol* 2007;**292**: H9289–H9238.

74. Dethlefsen SM, Shepro D, D'Amore PA. Comparison of the effects of mechanical stimulation on venous and arterial smooth muscle cells in vitro. *J Vasc Res* 1996;**33**: 405–413.

75. de Waard V, Arkenbout EK, Vos M, Mocking AI, Niessen HW, Stooker W, de Mol BA, Quax PH, Bakker EN, VanBavel E, Pannekoek H, de Vries CJ. TR3 nuclear orphan receptor prevents cyclic stretch-induced proliferation of venous smooth muscle cells. *Am J Pathol* 2006;**168**:2027–2035.

76. Cheng J, Wang Y, Ma Y, Chan BT, Yang M, Liang A, Zhang L, Li H, Du J. The mechanical stress-activated serum-, glucocorticoid-regulated kinase 1 contributes to neointima formation in vein grafts. *Circ Res* 2010;**107**:1265–1274.

77. Cheng J, Du J. Mechanical stretch simulates proliferation of venous smooth muscle cells through activation of the insulin-like growth factor-1 receptor. *Arterioscler Thromb Vasc Biol* 2007;**27**:1744–1751.

78. Mehta D, George SJ, Jeremy JY, Izzat MB, Southgate KM, Bryan AJ, Newby AC, Angelini GD. External stenting reduces long-term medial and neointimal thickening and platelet-derived growth factor expression in a pig model of arteriovenous bypass grafting. *Nat Med* 1998;**4**:235–239.

79. Murphy GJ, Newby AC, Jeremy JY, Baumbach A, Angelini GD. A randomized trial of an external Dacron sheath for the prevention of vein graft disease: the Extent study. *J Thorac Cardiovasc Surg* 2007;**134**:504.

80. Piola M, Ruiter M, Vismara R, Mastrullo V, Agrifoglio M, Zanobini M, Pesce M, Soncini M, Fiore GB. Full mimicking of coronary hemodynamics for ex-vivo stimulation of human saphenous veins. *Ann Biomed Eng* 2017;**45**:884–897.

81. Li DY, Brooke B, Davis EC, Mecham RP, Sorensen LK, Boak BB, Eichwald E, Keating MT. Elastin is an essential determinant of arterial morphogenesis. *Nature* 1998;**393**: 276–280.

82. Hornebeck W, Emonard H. The cell-elastin-elastase(s) interacting triade directs elastolysis. *Front Biosci* 2011;**16**:707–722.

83. Mochizuki S, Brassart B, Hinek A. Signaling pathways transduced through the elastin receptor facilitate proliferation of arterial smooth muscle cells. *J Biol Chem* 2002; **277**:44854–44863.

84. Koyama H, Raines EW, Bornfeldt KE, Roberts JM, Ross R. Fibrillar collagen inhibits arterial smooth muscle proliferation through regulation of Cdk2 inhibitors. *Cell* 1996;**87**:1069–1078.

85. Li S, Lao J, Chen BPC, Li Y-S, Zhao Y, Chu J, Chen K-D, Tsou T-C, Peck K, Chien S. Genomic analysis of smooth muscle cells in 3-dimensional collagen matrix. *Faseb J* 2003;**17**:97–99.

86. Liu B, Itoh H, Louie O, Kubota K, Kadono T, Kent C. The role of phospholipase C and phosphatidylinositol 3-kinase in vascular smooth muscle cell migration and proliferation. *J Surg Res* 2004;**120**:256–265.

87. Orr AW, Lee MY, Lemmon JA, Yurdagul A, Gomez MF, Bortz PDS, Wamhoff BR. Molecular mechanisms of collagen isotype-specific modulation of smooth muscle cell phenotype. *Arterioscler Thromb Vasc Biol* 2009;**29**:225–231.

88. Tanner FC, Yang Z-Y, Duckers E, Gordon D, Nabel G. J, Nabel EG. Expression of cyclin-dependent kinase inhibitors in vascular disease. *Circ Res* 1998;**82**:396–403.

89. Hollenbeck ST, Itoh H, Louie O, Faries PL, Liu BO, Kent KC. Type I collagen synergistically enhances PDGF-induced smooth muscle cell proliferation through pp60src-dependent crosstalk between the [alpha]2[beta]1 integrin and PDGF[beta] receptor. *Biochem Biophys Rese Comm* 2004;**325**:328–337.

90. Skinner MP, Raines EW, Ross R. Dynamic expression of alpha-1-beta-1 and alpha-2-beta-1 integrin receptors by human vascular smooth muscle cells - alpha-2-beta-1 integrin is required for chemotaxis across type-I collagen-coated membranes. *Am J Pathol* 1994;**145**:1070–1081.

91. Gotwals PJ, Chi-Rosso G, Lindner V, Yang J, Ling L, Fawell SE, Koteliansky VE. The a1b1 integrin is expressed during neointima formation in rat arteries and mediates collagen matrix reorganization. *J Clin Invest* 1996;**97**:2469–2477.

92. Kanda S, Kuzuya M, Ramos MA, Koike T, Yoshino K, Ikeda S, Iguchi A. Matrix metalloproteinase and avb3 integrin-dependent vascular smooth muscle cell invasion through a type I collagen lattice. *Arterioscler Thromb Vasc Biol* 2000;**20**: 998–1005.

93. Li SH, Chow LH, Pickering JG. Cell surface-bound collagenase-1 and focal substrate degradation stimulate the rear release of motile vascular smooth muscle cells. *J Biol Chem* 2000;**275**:35384–35392.

94. Carragher NO, Levkau B, Ross R, Raines EW. Degraded collagen fragments promote rapid disassembly of smooth muscle focal adhesions that correlates with cleavage of pp125(FAK), paxillin, and talin. *J Cell Biol* 1999;**147**:619–629.

95. Rocnik EF, Chan BMC, Pickering JG. Evidence for a role of collagen synthesis in arterial smooth muscle cell migration. *J Clin Invest* 1998;**101**:1889–1898.

96. Chapados R, Abe K, Ihida-Stansbury K, McKean D, Gates AT, Kern M, Merklinger S, Elliott J, Plant A, Shimokawa H, Jones PL. ROCK controls matrix synthesis in vascular smooth muscle cells: coupling vasoconstriction to vascular remodeling. *Circ Res* 2006;**99**:837–844.

97. Bendeck MP, Regenass S, Tom WD, Giachelli CM, Schwartz SM, Hart C, Reidy MA. Differential expression of a1 type VIII collagen in injured, platelet-derived growth factor-BB stimulated rat carotid arteries. *Circ Res* 1996;**79**:524–531.

98. Sibinga NES, Foster LC, Hsieh C-M, Perrella MA, Lee W-S, Endege WO, Sage EH, Lee M-E, Haber E. Collagen VIII is expressed by vascular smooth muscle cells in response to vascular injury. *Circ Res* 1997;**80**:532–541.

99. Plenz G, Dorszewski A, Breithardt G, Robenek H. Expression of type VIII collagen after cholesterol diet and injury in the rabbit model of atherosclerosis. *Arterioscler Thromb Vasc Biol* 1999;**19**:1201–1209.

100. Yasuda O, Zhang SH, Miyamoto Y, Maeda N. Differential expression of the alpha1 type VIII collagen gene by smooth muscle cells from atherosclerotic plaques of apolipoprotein-E-deficient mice. *J Vasc Res* 2000;**37**:158–169.

101. Illidge C, Kielty C, Shuttleworth A. Type VIII collagen: heterotrimeric chain association. *Int J Biochem Cell Biol* 2001;**33**:521–529.

102. Hou G, Mulholland D, Gronska MA, Bendeck MP. Type VIII collagen stimulates smooth muscle cell migration and matrix metalloproteinase synthesis after arterial injury. *Am J Pathol* 2000;**156**:467–476.

103. Hou G, Vogel W, Bendeck MP. The discoidin domain-receptor tyrosine kinase DDR1 in arterial wound repair. *J Clin Invest* 2001;**107**:727–735.

104. Adiguzel E, Hou G, Mulholland D, Hopfer U, Fukai N, Olsen BR, Bendeck MP. Migration and growth are attenuated in vascular smooth muscle cells with type VIII collagen-null alleles. *Arterioscler Thromb Vasc Biol* 2006;**26**:56–61.

105. Adiguzel E, Hou G, Sabatini PJB, Bendeck MP. Type VIII collagen signals via beta1 integrin and RhoA to regulate MMP-2 expression and smooth muscle cell migration. *Matrix Biol* 2013;**32**:332–341.

106. Lopes J, Adiguzel E, Gu S, Liu S-L, Hou G, Heximer SP, Assoian RK, Bendeck MP. Type VIII collagen mediates vessel wall remodeling after arterial injury and fibrous cap formation in atherosclerosis. *Am J Pathol* 2013;**182**:2241–2253.

107. Cherepanova OA, Pidkovka NA, Sarmento OF, Yoshida T, Gan Q, Adiguzel E, Bendeck MP, Berliner J, Leitinger N, Owens GK. Oxidized phospholipids induce type VIII collagen expression and vascular smooth muscle cell migration. *Circ Res* 2009;**104**:609–618.

108. Troyanovsky SM. Mechanism of cell-cell adhesion complex assembly. *Curr Opin Cell Biol* 1999;**11**:561–566.

109. Uglow EB, Slater S, Sala-Newby GB, Aguilera-Garcia CM, Angelini GD, Newby AC, George SJ. Dismantling of cadherin-mediated cell-cell contacts modulates smooth muscle proliferation. *Circ Res* 2003;**92**:1314–1321.

110. Williams E-J, Williams G, Howell FV, Skaper SD, Walsh FS, Doherty P. Identification of an N-cadherin motif that can interact with the fibroblast growth factor receptor and is required for axonal growth. *J Biol Chem* 2001;**276**:43879–43886.

111. Nelson WJ, Nusse R. Convergence of Wnt, β-catenin, and cadherin pathways. *Science* 2004;**303**:1483–1487.

112. Zhurinsky J, Shtutman M, Ben-Ze'ev A. Plakoglobin and β-catenin: protein interactions, regulation and biological roles. *J Cell Sci* 2000;**113**:3127–3139.

113. Tetsu O, McCormick F. β-catenin regulates expression of cyclin D1 in colon carcinoma cells. *Nature* 1999;**398**:422–426.

114. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B, Kinzler KW. Identification of c-myc as a target of the APC pathway. *Science* 1998;**281**:1509–1512.

115. Rahmani M, Read J, Carthy J, Luo Z, Luo H, Si X, Wallace A, Rennie P, McManus B. Versican promoter is a target for the β-catenin/TCF-4 transcription factor via protein kinase B/glycognen synthase kinase-3β signaling in vascular smooth muscle cells. *Cardiovasc Pathol* 2004;**13**:56.

116. Gradl D, Kuhl M, Wedlich D. The Wnt/Wg signal transducer β-catenin controls fibronectin expression. *Mol Cell Biol* 1999;**19**:5576–5587.

117. Brabletz T, Jung A, Dag S, Hlubek F, Kirchner T. βcatenin regulates the expression of the matrix metalloproteinase-7 in human colorectal cancer. *Am J Pathol* 1999;**155**:1033–1038.

118. Hlubek F, Spaderna S, Jung A, Kirchner T, Brabletz T. βcatenin activates a coordinated expression of the proinvasive factors laminin-5 ψ2 chain and MT1-MMP in colorectal carcinomas. *Int J Cancer* 2004;**108**:321–326.

119. Noren N K, Liu B P, Burridge K, Kreft B. p120 catenin regulates the actin cytoskeleton via Roh family GTPases. *J Cell Biol* 2000;**150**:567–579.

120. Skaper S, Facci L, Williams G, Williams E-J, Walsh F, Doherty P. A dimeric version of the short N-Cadherin binding motif HAVDI promotes neuronal cell survival by activating an N-Cadherin/fibroblast growth factor receptor signalling cascade. *Mol Cell Neurosci* 2004;**26**:17–23.

121. Nieman MT, Prudoff RS, Johnson KR, Wheelock MJ. N-cadherin promotes motility in human breast cancer cells regardless of their E-cadherin expression. *J Cell Biol* 1999;**147**:631–643.

122. Utton MA, Eickholt B, Howell FV, Wallis J, Doherty P. Soluble N-cadherin stimulates fibroblast growth factor receptor dependent neurite outgrowth and N-cadherin and the fibroblast growth factor receptor co-cluster in cells. *J Neurochem* 2001;**76**:1421–1430.

123. Cavallaro U, Niedermeyer J, Fuxa M, Christofori G. N-CAM modulates tumour-cell adhesion to matrix by inducing FGF-receptor signalling. *Nat Cell Biol* 2001;**3**:650–657.

124. Lyon CA, Johnson JL, Williams H, Sala-Newby GB, George SJ. Soluble N-cadherin over-expression reduces features of atherosclerotic plaque instability. *Arterioscler Thromb Vasc Biol* 2009;**29**:195–201.

125. Dwivedi A, Slater S, George S. MMP-9 and -12 cause N-cadherin shedding and thereby β-catenin signalling and vascular smooth muscle cell proliferation. *Cardiovasc Res* 2009;**81**:178–186.

126. Quasnichka H, Slater S, Beeching C, Boehm M, Sala-Newby G, George S. Regulation of smooth muscle cell proliferation by β-catenin/TCF signaling involves modulation of cyclin D1 and p21 expression. *Circ Res* 2006;**99**:1329–1337.

127. Slater SC, Koutsouki E, Jackson CL, Bush RC, Angelini GD, Newby AC, George SJ. R-cadherin:β-catenin complex and its association with vascular smooth muscle cell proliferation. *Arterioscler Thromb Vasc Biol* 2004;**24**:1204–1210.

128. Jones M, Sabatini PJB, Lee FSH, Bendeck MP, Langille BL. N-cadherin upregulation and function in response of smooth muscle cells to arterial injury. *Arterioscler Thromb Vasc Biol* 2002;**22**:1972–1977.

129. Koutsouki E, Aguilera-Garcia CM, Sala-Newby GB, Newby AC, George SJ. Cell-cell contact by cadherins provides an essential survival signal to migrating smooth muscle cells. *Eur Heart J* 2003;**24**:1838.

130. Blindt R, Bosserhoff A, Dammers J, Krott N, Demircan L, Hoffmann R, Hanrath P, Weber CFV. Downregulation of N-cadherin in the neointima stimulates migration of smooth muscle cells by RhoA deactivation. *Cardiovasc Res* 2004;**62**: 212–222.

131. Sabatini P, Zhang M, Silverman-Gavrila R, Bendeck M, Langille BL. Homotypic and endothelial cell adhesions via N-cadherin regulate polarity and migration of vascular smooth muscle cells. *Circ Res* 2008;**103**:405–412.

132. Wang X, Xiao Y, Mou Y, Zhao Y, Blankesteijn M, Hall JL. β-catenin/T-cell factor signaling cascade in vascular remodelling. *Circ Res* 2002;**90**:340–347.

133. Wang X, Adhikari N, Li Q, Hall JL. The LDL receptor related protein LRP6 regulates proliferation and survival through the Wnt cascade in vascular smooth muscle cells. *Am J Physiol Heart Circulatory Physiol* 2004;**287**:H2376–H2383.

134. Ezan J, Leroux L, Barandon L, Dufourcq P, Jaspard B, Moreau C, Allieres C, Daret D, Couffinhal T, Duplaa C. FrzA/sFRP-1, a secreted antagonist of the Wnt-Frizzled pathway, controls vascular cell proliferation in vitro and in vivo. *Cardiovasc Res* 2004; **63**:731–738.

135. Lv L, Zhou Z, Huang X, Zhao Y, Zhang L, Shi Y, Sun M, Zhang J. Inhibition of peptidyl-prolyl cis/trans isomerase Pin1 induces cell cycle arrest and apoptosis in vascular smooth muscle cells. *Apoptosis: Int J Programmed Cell Death* 2010;**15**: 41–54.

136. Sklepkiewicz P, Schermuly RT, Tian X, Ghofrani HA, Weissmann N, Sedding D, Kashour T, Seeger W, Grimminger F, Pullamsetti SS. Glycogen synthase kinase 3beta contributes to proliferation of arterial smooth muscle cells in pulmonary hypertension. *PLoS ONE* 2011;**6**:e18883.

137. Tsaousi A, Williams H, Lyon C, Taylor V, Swain A, Johnson J, George S. Wnt4/β-catenin signalling induces VSMC proliferation and is associated with intimal thickening. *Circ Res* 2011;**108**:427–436.

138. Yu X-M, Wang L, Li J-F, Liu J, Li J, Wang W, Wang J, Wang C. Wnt5a inhibits hypoxia-induced pulmonary arterial smooth muscle cell proliferation by downregulation of β-catenin. *Am J Physiol–Lung Cellular Mol Physiol* 2013;**304**:L103–L111.

139. Zhuang Y, Mao JQ, Yu M, Dong LY, Fan YL, Lv ZQ, Xiao MD, Yuan ZX. Hyperlipidemia induces vascular smooth muscle cell proliferation involving Wnt/beta-catenin signaling. *Cell Biol Int* 2016;**40**:121–130.

140. Marchand A, Atassi F, Gaaya A, Leprince P, Le Feuvre C, Soubrier F, Lompré A-M, Nadaud S. The Wnt/beta-catenin pathway is activated during advanced arterial aging in humans. *Aging Cell* 2011;**10**:220–232.

141. Wu X, Wang J, Jiang H, Hu Q, Chen J, Zhang J, Zhu R, Liu W, Li B. Wnt3a activates beta1-integrin and regulates migration and adhesion of vascular smooth muscle cells. *Mol Med Rep* 2014;**9**:1159–1164.

142. Williams H, Mill CA, Monk BA, Hulin-Curtis S, Johnson JL, George SJ. Wnt2 and WISP-1/CCN4 induce intimal thickening via promotion of smooth muscle cell migration. *Arterioscler Thromb Vasc Biol* 2016;**36**:1417–1424.

143. Riascos-Bernal DF, Chinnasamy P, Gross JN, Almonte V, Egaña-Gorroño L, Parikh D, Jayakumar S, Guo L, Sibinga NES. Inhibition of smooth muscle β-catenin hinders neointima formation after vascular injury. *Arteriosclerosis Thromb Vasc Biol* 2017;**37**: 879–888.

144. Chen L, Zhuang J, Singh S, Wang K, Xiong M, Xu D, Chen W, Pang J, Xu Y, Li X. XAV939 Inhibits intima formation by decreasing vascular smooth muscle cell proliferation and migration through blocking wnt signaling. *J Cardiovasc Pharmacol* 2016; **68**:414–424.

145. Williams H, Slater S, George SJ. Suppression of neointima formation by targeting β-catenin/TCF pathway. *Biosci Rep* 2016;**36**:e00427.

146. Hulin-Curtis S, Williams H, Wadey KS, Sala-Newby GB, George SJ. Targeting Wnt/β-catenin activated cells with dominant-negative N-cadherin to reduce neointima formation. *Mol Ther–Meth Clin Develop* 2017;**5**:191–199.